ANIX (Anixa Biosciences) Shares Outstanding (EOP): 33.92 Mil (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.79
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Shares Outstanding (EOP)?

Anixa Biosciences ANIX +5.88% 27 Shares Outstanding (EOP) is 33.92 Mil as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Anixa Biosciences's shares outstanding for the quarter that ended in Apr. 2026 was 33.92 Mil.

Anixa Biosciences's quarterly shares outstanding increased from Jan. 2026 (33.46 Mil) to Apr. 2026 (33.92 Mil). It means Anixa Biosciences issued new shares from Jan. 2026 to Apr. 2026 .

Anixa Biosciences's annual shares outstanding increased from Oct. 2024 (32.20 Mil) to Oct. 2025 (33.01 Mil). It means Anixa Biosciences issued new shares from Oct. 2024 to Oct. 2025 .


Anixa Biosciences  (NAS:ANIX) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Anixa Biosciences Shares Outstanding (EOP) Related Terms


Anixa Biosciences Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Shares Outstanding (EOP) Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.05 30.91 31.15 32.20 33.01

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.21 32.82 33.01 33.46 33.92

ANIX vs PYPD, LONA, SGMO: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Anixa Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Shares Outstanding (EOP) falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 33.92 Mil mean?
Anixa Biosciences (ANIX) has a Shares Outstanding (EOP) of 33.92 Mil as of Apr. 2026. The total shares a company has outstanding, at period-end. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Shares Outstanding (EOP) too high?
Anixa Biosciences' current Shares Outstanding (EOP) is 33.92 Mil. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Shares Outstanding (EOP) compare to PYPD and LONA?
Anixa Biosciences' Shares Outstanding (EOP) of 33.92 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Shares Outstanding (EOP) is 33.92 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Shares Outstanding (EOP) of 33.92 Mil. The current Shares Outstanding (EOP) is 33.92 Mil. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Shares Outstanding (EOP) is 33.92 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.79
Price